Navigation Links
Advanced Life Sciences Announces Third Quarter 2008 Financial Results
Date:11/6/2008

CHICAGO, Nov. 6 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (Nasdaq: ADLS), a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and respiratory diseases, today announced its financial results for the third quarter ended September 30, 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080218/ALSLOGO)

The net loss available to common shareholders for the three months ended September 30, 2008 was $13.1 million or ($0.34) per share compared to $5.9 million or ($0.21) per share for the same period last year. The increase in the net loss is primarily attributable to $10.0 million of milestone expenses due to Abbott Laboratories as part of the cethromycin licensing agreement that were triggered as a result of the cethromycin new drug application (NDA) submission to the U.S. Food and Drug Administration (FDA) at the end of the third quarter.

"We achieved multiple significant milestones in the third quarter including establishing a major partnership, valued at more than $100 million, for the development and commercialization of cethromycin with Wyeth in the Asia Pacific region, and completing our cethromycin NDA submission in community acquired pneumonia," said Michael T. Flavin, Ph.D., chairman and chief executive officer of Advanced Life Sciences. "We believe that these are major accomplishments that significantly enhance the value of our lead drug candidate and underscore our company's emerging role in the large and growing global antibiotics market. We look forward to continuing this momentum through the fourth quarter and into
'/>"/>

SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
3. Advanced Cell Technology Announces Proposed Financing
4. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
5. Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry
6. Advanced Life Sciences to Present at 2007 UBS Global Life Sciences Conference
7. CeloNova BioSciences Announces Worlds First Line of Fully Color-Coded Embolic Particles at CIRSE: Embozene(TM) Color-Advanced Microspheres
8. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
9. Advanced Bionics Deploys CEVA-TeakLite(TM) DSP Core to Enhance Its Harmony(TM) HiResolution(R) Bionic Ear System
10. NIH Announces Advanced Cell Technologys Single Cell Embryo Biopsy Technique as a Means to Derive Embryonic Stem Cells to be Considered for Federal Funding
11. Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... DIEGO , Aug. 3, 2015  Aethlon Medical, Inc. ... biofiltration devices to treat life-threatening diseases, today announced that ... conference call and webcast on Thursday, August 13, 2015 ... and webcast will follow the release of fiscal 2016 ... will be available approximately two hours after the call ...
(Date:8/3/2015)... -- E-QURE Corp. (OTCQB: EQUR), a Delaware ... Therapy device ("BST Device"), a new and novel electrotherapy ... wounds, today announced that the Company has signed its ... in medical devices, for the marketing and distribution of ... years old, sales, marketing and distribution company in ...
(Date:8/3/2015)... , Aug. 3, 2015   Intrexon Corporation ... release first half and second quarter 2015 financial results ... , 2015.  The Company will host a conference call ... provide a general business update. The conference ... and 1-412-902-4262 (International), and asking to join the "Intrexon ...
(Date:8/3/2015)... According to a new market ... Asia to Witness Highest Growth ... cell culture market was valued at US$ 586.1 Mn in ... of 29.1% to account for US$ 2,717.6 Mn by ... 3D cell culture refers to a ...
Breaking Biology Technology:Aethlon Medical To Host First Quarter Fiscal 2016 Investor Call on August 13, 2015 2E-QURE Corp Signs Second Distribution Agreement in Israel 2E-QURE Corp Signs Second Distribution Agreement in Israel 3Intrexon to Announce First Half and Second Quarter 2015 Financial Results and Host Conference Call on August 10th 2Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 2Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 3Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 4
... Corporation (Nasdaq: DNDN ) today announced that management ... in San Francisco on Thursday, January 15, 2009 at 11:00 ... presentation will be accessible through the Investor Relations section of ... to listen to the live webcast, it will be archived ...
... CRANBURY, N.J., Jan. 8 Amicus Therapeutics (Nasdaq: ... J. Barer, Ph.D., to its Board of Directors. ... Officer of Celgene Corporation. As an industry veteran, ... and a reputation as a trusted and respected leader ...
... CAMBRIDGE, Mass. January 7, 2008 Researchers from Harvard ... for the first time, a repulsive quantum mechanical force that ... new nanotechnology applications. , The study, led by Federico Capasso, ... of Engineering and Applied Science (SEAS), will be published as ...
Cached Biology Technology:Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors 2Researchers measure elusive repulsive force from quantum fluctuations 2
(Date:7/31/2015)... juli 2015 Den 10. internationale konference om ... den 22. - 25. oktober i Shenzhen ... 10-års fødselsdag i år. Siden starten i 2006 er ... på ,omik,-feltet, og er en af de mest dynamiske, ... fokuserer på nylige gennembrud og fremskridt inden for ,omik,-forskning, ...
(Date:7/31/2015)... 31 de julio de 2015 BGI llevará a ... ) del 22 al 25 de octubre de 2015, ... La conferencia celebra su décimo aniversario este año. Desde ... una de las reuniones anuales más influyentes del mundo ... de las conferencias científicas más dinámicas, entusiastas y amenas. ...
(Date:7/31/2015)... China , 31 de julho de 2015 /PRNewswire/ ... (ICG-10, www.icg-10.org ) será realizada pela BGI de 22-25 ... . A conferência está celebrando seu ... em 2006, a ICG se tornou uma das reuniões ... um dos encontros científicos mais dinâmicos, entusiastas e prazerosos. ...
Breaking Biology News(10 mins):Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3
... Evolution Group participated in an international research that has resulted ... fly species. The study also includes new data on the ... sixty million years. The research, published in Nature, was ... over the world and consisted in the analysis of the ...
... Inc. and the Prostate Cancer Foundation today announced they ... Program (for Special Team Amplification of Research), an innovative ... heat in cancer therapy to treat prostate cancer, as ... is being launched for the first phase of research ...
... (November 15, 2007) -- In response to the need ... populations of the threatened staghorn coral, Diego Lirman, Ph.D., ... Rosenstiel School of Marine and Atmospheric Science (RSMAS) have ... of staghorn corals. The goals of the coral ...
Cached Biology News:Genome comparison of 12 fruit fly species 2Safeway Inc. and PCF to fund landmark prostate cancer research collaboration 2Safeway Inc. and PCF to fund landmark prostate cancer research collaboration 3Safeway Inc. and PCF to fund landmark prostate cancer research collaboration 4New south Florida nursery to focus on staghorn corals 2
... the ultimate in utility and flexibility press-to-seal ... the needs of the researcher. They are ... or as sheet material that can be ... isolators are autoclavable and non-cytotoxic and can ...
2,4-Dinitrophenyl hapten is conjugated to Human Serum Albumin (HSA) protein through lysine....
IC50: 3 ng/ml · Limit of detection: 0.5 ng/ml...
Antibodies were affinity purified using epitopes specific to PPP1CC immobilized on solid support....
Biology Products: